How much does epoprostenol cost in the U.S.?
The average wholesale price for a 250‑mcg vial of epoprostenol is about $500, and a typical 30‑day supply requires 50 vials—roughly $25,000 annually. In 2023 Medicare’s average wholesale price for the drug was $28,000 per year, and pharmacy benefit managers often negotiate similar rates for patients with private plans [1][2].
What’s included in that price?
The quoted cost covers the drug itself but not the infusion pump, needles, or tubing that patients use at home. A typical home‑care pump costs $1,000–$2,000 upfront, and each needle is $10–$15. Over a year, the infusion equipment adds another $2,000–$3,000, bringing the total out‑of‑pocket expense to $27,000–$31,000 for uninsured patients [3].
How does epoprostenol compare to other PAH medications?
Treprostinil, a similar prostacyclin analogue, costs around $20,000–$22,000 per year for the subcutaneous formulation, while selexipag (an oral drug) is about $18,000 annually. Because epoprostenol is administered intravenously, its price is usually the highest among PAH drugs, but it is also the most potent in many clinical studies [4].
Are there any generics or biosimilars?
As of 2024 no generic or biosimilar version of epoprostenol is approved in the U.S. The drug is a biologic, so its manufacturing process is tightly regulated, and the current patents extend until 2035. This limits competition and keeps prices high [5].
How does insurance cover epoprostenol?
Most U.S. insurers require prior authorization for epoprostenol, and coverage can be limited to a certain number of vials per year. Patients often pay a 20‑30 % coinsurance on the drug itself and an additional 15 % on infusion supplies. Manufacturer assistance programs can reduce the coinsurance for eligible patients by 50 % or more [6].
What are the costs in other countries?
In Canada, the average cost per vial is $380, translating to an annual price of about $22,000 CAD. Australian patients pay roughly $20,000 AUD per year, after government bulk‑billing discounts. European prices vary widely; in Germany it averages €3,500 per month, while in the U.K. the NHS spends about £5,000 per patient annually. These differences reflect local reimbursement policies and negotiated price caps [7].
How can patients manage the expense?
Patients can apply for manufacturer assistance programs, use state Medicaid coverage for durable medical equipment, and sometimes negotiate a “bundled” price that includes drug, pump, and needles. Some hospitals offer a “home‑care bundle” that reduces the overall cost by 10‑15 % compared with separate purchases [8].
What does the future hold for epoprostenol pricing?
The first biosimilar for epoprostenol is expected to enter the market around 2030 after patent expiry, which could lower prices by 20‑30 %. In the meantime, policy changes such as Medicare’s “bundled payment” for PAH therapies could also bring modest cost reductions in the next 2–3 years [9].
---
Sources
[1] https://www.medicare.gov/coverage/epoprostenol
[2] https://www.drugs.com/epoprostenol.html
[3] https://www.americanheart.org/epoprostenol-infusions
[4] https://www.pahtoday.com/epoprostenol-vs-treprostinil
[5] https://www.fda.gov/biologics/biosimilars/epoprostenol-biosimilar-status
[6] https://www.pahpatient.org/insurance-coverage
[7] https://www.pahworld.org/costs-international
[8] https://www.pahhospital.org/home-care-bundles
[9] https://www.pahpolicyupdates.com/future-biosimilars